



16 May 2024

Sydney, Australia

Nyrada General Meeting Results

Nyrada Inc (ASX:NYR) (“Nyrada” or “Company”), a drug development company specialising in novel small molecule therapeutics, announces the results of today’s General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

All resolutions were passed and decided by way of a poll.

-ENDS-

About Nyrada Inc

Nyrada is a drug discovery and development company specialising in novel small-molecule drugs to treat neurological and cardiovascular diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a drug to treat brain injury, specifically traumatic brain injury and stroke, and a cholesterol lowering drug. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Mr David Franks, Company Secretary on behalf of the Board.

Investor & Corporate Enquiries:

Dimitri Burshtein

T: 02 9498 3390

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong

Morrow Sodali

T: 02 8234 0111

E: c.strong@morrrowsodali.com



Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

Disclosure of Proxy Votes

Nyrada Inc

Extraordinary General Meeting

Thursday, 16 May 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Ratification of Prior Issue of 23,400,000 CDIs under ASX Listing Rule 7.4	P	56,576,068	56,142,309 99.23%	226,045 0.40%	278,333	207,714 0.37%	56,350,023 99.60%	226,045 0.40%	278,333	Passed
2 Approval of Issue of CDIs to John Moore, Chairman and Director of the Company	P	62,962,979	62,481,239 99.23%	278,396 0.44%	235,000	203,344 0.32%	62,684,583 99.56%	278,396 0.44%	235,000	Passed
3 Approval of Issue of CDIs to Marcus Frampton, Director of the Company	P	63,017,327	62,555,587 99.27%	258,396 0.41%	420,075	203,344 0.32%	62,758,931 99.59%	258,396 0.41%	420,075	Passed
4 Approval of Issue of CDIs to Dr Ruediger Weseloh, Director of the Company	P	63,102,402	62,640,662 99.27%	258,396 0.41%	335,000	203,344 0.32%	62,844,006 99.59%	258,396 0.41%	335,000	Passed
5 Approval of Issue of CDIs to Dr Ian Dixon, Director of the Company	P	53,088,369	50,790,999 95.67%	2,094,026 3.94%	10,349,033	203,344 0.38%	50,994,343 96.06%	2,094,026 3.94%	10,349,033	Passed
6 Approval of Issue of Broker Options	P	61,208,329	60,772,625 99.29%	232,360 0.38%	2,129,073	203,344 0.33%	60,975,969 99.62%	232,360 0.38%	2,129,073	Passed

